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OPEN
ORIGINAL ARTICLE
Associations between functional polymorphisms and response
to biological treatment in Danish patients with psoriasis
ND Loft1, L Skov1, L Iversen2, R Gniadecki3, TN Dam4, I Brandslund5, HJ Hoffmann6, MR Andersen7, RB Dessau8, AC Bergmann9,
NM Andersen9, PS Andersen10, S Bank9, U Vogel11 and V Andersen9,12,13
Biological agents including anti-tumor necrosis factor (anti-TNF; adalimumab, inﬂiximab, etanercept) and anti-interleukin-12/13
(IL12/23; ustekinumab) are essential for treatment of patients with severe psoriasis. However, a signiﬁcant proportion of the patients
do not respond to a speciﬁc treatment. Pharmacogenetics might be a way to predict treatment response. Using a candidate gene
approach, 62 mainly functional single-nucleotide polymorphisms (SNPs) in 44 different genes were evaluated in 478 Danish
patients with psoriasis undergoing 376 series of anti-TNF treatment and 230 series of ustekinumab treatment. Associations between
genetic variants and treatment outcomes (drug survival and Psoriasis Area Severity Index reduction) were assessed using logistic
regression analyses (crude and adjusted for gender, age, psoriatic arthritis and previous treatment). After correction for multiple
testing controlling the false discovery rate, six SNPs (IL1B (rs1143623, rs1143627), LY96 (rs11465996), TLR2 (rs11938228, rs4696480)
and TLR9 (rs352139)) were associated with response to anti-TNF treatment and 4 SNPs (IL1B (rs1143623, rs1143627), TIRAP
(rs8177374) and TLR5 (rs5744174)) were associated with response to ustekinumab treatment (qo0.20). The results suggest that
genetic variants related to increased IL-1β levels may be unfavorable when treating psoriasis with either anti-TNF or ustekinumab,
whereas genetic variants related to high interferon-γ levels may be favorable when treating psoriasis with ustekinumab.
The Pharmacogenomics Journal advance online publication, 11 July 2017; doi:10.1038/tpj.2017.31
INTRODUCTION
Psoriasis is a common skin disease characterized by an inﬂamed,
red scaly skin that affects 2–4% of the world’s population.1
Psoriasis involves a dysregulated immune system and is regarded
as a T cell-mediated immune disease with a mixed upregulation
of T helper type 1/17 (Th1/Th17) cytokines,2 including tumor
necrosis factor-α (TNF-α), interleukin (IL)-12, IL-23, IL-22, interferon-
γ (IFN-γ) and IL-17A.3 Biological drugs targeting TNF-α (inﬂiximab
adalimumab, etanercept) and the p40 subunit of IL12 and IL23
(ustekinumab) are essential for treatment of patients with severe
psoriasis. However, approximately one-third of the patients do not
respond to a speciﬁc treatment4 and require a change in
treatment. The consequences of this ‘trial and error’ policy results
in periods of nonoptimal treatment for the patient and increased
treatment costs, thus calling for ways of identifying the best
treatment for each patient. Pharmacogenetics might be a way of
predicting treatment response. However, little is known regarding
the interaction between genetics and biological drugs in relation
to psoriasis.5 Pharmacogenetics has been more thoroughly
investigated in inﬂammatory bowel disease and rheumatoid
arthritis, where polymorphisms in genes encoding Toll-like
receptors (TLRs) and NOD-like receptors have been found to be
associated with response to anti-TNF drugs.6–10 Nuclear factor-κB
plays a major role in controlling inﬂammation and is an important
regulator of pathways leading to expression of cytokines in
psoriasis, including IL-1β (http://www.bu.edu/nf-kb/gene-
resources/target-genes/). Nuclear factor-κB can be activated by
TLRs and NOD-like receptors. The objective of this study was to
determine whether variants in genes involved in nuclear factor-κB,
TNF-α and pattern recognition (TLRs and NOD-like receptors)
pathways could be used to predict response and nonresponse in
patients with psoriasis who are treated either with anti-TNF or
ustekinumab.
MATERIALS AND METHODS
Cohort
Blood clot samples, sent for Mycobacterium tuberculosis screening,
were obtained from Statens Serum Institut (Copenhagen, Denmark);
the Department of Respiratory Diseases B and the Department of Clinical
Microbiology, Aarhus University Hospital (Aarhus, Denmark); the Depart-
ment of Biochemistry, Hospital of Lillebaelt (Vejle, Denmark); the
Department of Clinical Biochemistry, Herlev and Gentofte Hospital
(Hellerup, Denmark); and the Department of Biochemistry, Hospital of
Slagelse (Slagelse, Denmark) from September 2009 through July 2015 as
described earlier.6–9 Screening for Mycobacterium tuberculosis before
initiation of treatment with biological drugs is generally performed in
Denmark. Patients were identiﬁed by linking the unique personal
identiﬁcation number of Danish citizens (CPR number) from each blood
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sample with the Danish national database DERMBIO (Figure 1). DERMBIO is
a nationwide registry including all biological administered treatments for
psoriasis in Denmark, with a 100% coverage of treatments administered in
academic hospitals (88% of treatments) and an estimated coverage of
480% for private clinics (12% of treatments).11 Prospective data were
collected from DERMBIO and were supplemented with and validated by
information from patient records. If a patient had been given more than
one anti-TNF treatment, only the ﬁrst treatment was included. If a patient
had been treated with both anti-TNF and ustekinumab, then both
treatment series were included (Figure 1). Patient data included gender;
body mass index; age at baseline and at diagnosis; Psoriasis Area Severity
Index (PASI)12 and dermatology life quality index scores at baseline,
3 months and 6 months after initiation of the biological drug; side effects;
psoriatic arthritis; concomitant methotrexate treatment; drug name; and
Figure 1. Selection of patients included in the study.
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treatment number. The baseline was deﬁned as day of start of treatment
(±14 days), the 3-month visit as 90 days (±45 days) and the 6-month visit as
180 days (±45 days). If more visits were recorded within the periods, the
ones closest to the baseline and 3- and 6-month marks were chosen.
Ethical considerations
The study was conducted in accordance with the Declaration of
Helsinki and was approved by the local regional ethics committees
(M-20100153 and S-20120113) and the Danish Data Protection Agency
(J. 2010-41-4719 and 2008-58-035). The regional ethics committees gave
exemption from obtaining informed consent because information had no
health-related impact on subjects.
Response criteria
We chose drug survival (the period of time that a patient receives
biological treatment) to be our primary response criterion. Patients treated
for 225 days (equivalent to 6 months+45 days) or more were categorized
as responders. Patients who stopped treatment before 225 days were
categorized as either primary nonresponders or secondary nonresponders.
Patients who initially had a response (a relative reduction in PASI of at least
75%—or information from the doctor/health personnel in the patient
records that a beneﬁcial effect had been achieved), but where the
response diminished over time or treatment was stopped for other reasons
(for example, side effects), were categorized as secondary nonresponders,
and those who never responded to treatment were categorized as primary
nonresponders. Patients who stopped treatment before 225 days for other
reasons than lack of effect, and where no information of response was
available, were excluded from further analysis.
As our secondary response criteria, we evaluated response based on
relative reduction in PASI score after 3 months. Patients who achieved
reduction of o50% were categorized as being nonresponders, those
with a reduction of between 50 and 75% were categorized as being
intermediate responders and those with a reduction of ⩾ 75% were
categorized as being good responders. Patients with missing baseline PASI
but a PASI score of 0 after 3 months (equivalent to a PASI reduction of
100%) were categorized as good responders.
Genotyping
We selected genes involved in nuclear factor-κB, TNF-α and pattern
recognition pathways as described by Bank et al.6 and Sode et al.8 Brieﬂy,
candidates were found by searching for ‘polymorphism AND Gene name
AND (reporter gene OR luciferase OR ELISA OR RT-PCR OR ﬂow cytometry OR
EMSA)’ and the single-nucleotide polymorphism (SNP) candidates were
chosen based on the reported functionality, association with autoimmune
diseases or association with response.6–8 A list of all SNPs studied is
presented in Supplementary Table 1a. DNA extraction (Maxwell 16 LEV
Blood DNA Kit; Promega, Madison, WI, USA) was performed as described
by Bank et al.13
The polymorphisms were genotyped with PCR-based KASP genotyping
assays by LGC Genomics (LGC Genomics, Hoddesdon, UK; http://www.
lgcgenomics.com/). FGF2 (rs308379) and TLR10 (rs11096957) were only
genotyped in 376 patients; the rest of the SNPs were genotyped in all
patients.
Linking disequilibrium was calculated using SNAP (http://archive.broad
institute.org/mpg/snap/) using as reference the Central Europeans in the
1000 Genomes.14
As a quality control, all SNPs were replicated in 94 randomly selected
samples, yielding 499% identical genotypes. The average call rate for all
SNPs was 497%. None of the patients had the minor allele of IL-12RB2
(rs11810249). IL-18 (rs187238) and IL-18 (rs360719) were in complete
linking disequilibrium (r2 = 1.00), and rs360719 was therefore excluded
from further analysis.
Power analysis
At the 5% signiﬁcance level and a minor allele frequency of 0.05, 0.25
and 0.45, we had 480% power of detecting a dominant effect with an
odds ratio (OR) of 2.0, 1.8 and 2.2, respectively, for the anti-TNF cohort and
an OR of 2.3, 2.2 and 3.3, respectively, for the ustekinumab cohort. The
Genetic Power Calculator15 was used for power calculations, setting
‘prevalence’ to 0.33, d′ to 1, type 1 error rate to 0.05 and number of cases
and control/case ratio was based on data described in Supplementary
Table 2a.
Statistical analysis
Under a dominant model logistic regression analysis was used to compare
genotypes in responders against those in primary nonresponders (R vs PN),
and genotypes in responders and secondary nonresponders combined
against those in primary nonresponders (R+S vs PN), as genetics may not
have main effects on secondary nonresponse. For our second outcome, we
compared good responders against nonresponders (G vs N) and good and
intermediate responders against nonresponders (G+I vs N) under a
dominant model. Crude ORs and ORs adjusted for gender, age, psoriatic
arthritis and previous biological treatment are reported (Supplementary
Tables 3). Genotype distributions for all patients and for each outcome
tested are presented in Supplementary Table 1b. We corrected for multiple
testing by controlling the overall false discovery rate (FDR) at 20%,16 with
computation of FDR-adjusted P-values (referred to as q-values) based on all
P-values presented in Supplementary Tables 3. The q-value describes the
expected proportion of false positives among all associations at least as
extreme as the observed association. The χ2 test was used to compare
differences in categorical outcomes of clinical and demographic charac-
teristics, and for continuous outcomes a one-way analysis of variance was
used. Statistical analyses were performed using Stata version 14 (StataCorp
LP, College Station, TX, USA). Computation of q-values was performed
using the inbuilt p-adjust function in R (Vienna, Austria) using the
Benjamini–Hochberg method.
RESULTS
Study population
A total of 480 patients with blood clot samples available were
registered in DERMBIO as having psoriasis. Two patients were
excluded because of participation in blinded clinical trials, leaving
478 patients with 631 treatment series. These treatment series
involved 395 patients treated with anti-TNF and 236 patients
treated with ustekinumab. Nineteen of the patients treated with
anti-TNF were excluded from analysis because of inconclusive
responses, resulting in a cohort of 376 patients treated with anti-
TNF. Six of the patients treated with ustekinumab were excluded
from analysis because of inconclusive responses, resulting in a
cohort of 230 patients treated with ustekinumab (Figure 1). The
clinical and demographic characteristics of all patients are given
in Table 1, including stratiﬁcation for treatment. Characteristics of
all patients registered in DERMBIO are presented in Supple-
mentary Table 2c.
Patients treated with anti-TNF
Looking at primary outcome of the 376 patients treated with
anti-TNF, 294 (78%) were responders, 30 (8%) were secondary
nonresponders and 52 (14%) were primary nonresponders
(Supplementary Table 2a). Statistically fewer females than males
responded when treated with anti-TNF (Po0.001). Regarding
secondary outcome, among patients treated with anti-TNF, 250
had PASI scores available at baseline and after 3 months. Of these,
163 (65%) were good responders, 41 (16%) were intermediate
responders and 46 (18%) were nonresponders (Supplementary
Table 2b). Previous treatment with ustekinumab was associated
with nonresponse (P= 0.02).
Polymorphisms associated with anti-TNF treatment
Associations of each SNP and response to anti-TNF therapy were
evaluated using drug survival as outcome, comparing genotypes
of responders with those of primary nonresponders under a
dominant model. Four of the analyzed SNPs showed nominal
statistical signiﬁcance (Po0.05) for both crude and adjusted ORs
(Supplementary Table 3). After controlling for the FDR, only TLR9
(rs352139) (OR: 2.42, P= 0.0044, q= 0.19) remained signiﬁcant
(Table 2). Associations of each SNP and response to anti-TNF
therapy were then evaluated using PASI reduction as outcome,
comparing genotypes of good responders with those of non-
responders under a dominant model. Six of the analyzed SNPs
SNPs associated with biological treatment
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showed nominal statistical signiﬁcance (Po0.05) for both crude
and adjusted ORs (Supplementary Table 4). After controlling for
the FDR, 5 of the SNPs remained signiﬁcant, whereof the variant
alleles of IL1Β (rs1143623) (OR: 0.35, P= 0.0041, q= 0.19), IL1Β
(rs1143627; r2 = 0.83) (OR: 0.28, P= 0.0016, q= 0.19), LY96
(rs11465996) (OR: 0.33, P= 0.0044, q= 0.19), TLR2 (rs11938228)
(OR: 0.30, P= 0.0019, q= 0.19) and TLR2 (rs4696480; r2 = 0.48) (OR:
0.22, P= 0.0032, q= 0.19) were all associated with nonresponse to
treatment (Table 2).
Patients treated with ustekinumab
Looking at primary outcome of the 230 patients treated with
ustekinumab, 201 (87%) were responders, 2 (1%) were secondary
nonresponders and 27 (12%) were primary nonresponders
(Supplementary Table 2a). Previous treatment with anti-TNF was
associated with nonresponse (P= 0.02). Regarding secondary
outcome, of the patients treated with ustekinumab, 143 had PASI
scores available at baseline and after 3 months. Of these, 80 (56%)
were good responders, 29 (20%) were intermediate responders
and 34 (24%) were nonresponders (Supplementary Table 2b)
Previous treatment with anti-TNF was associated with nonre-
sponse (P= 0.005).
Polymorphisms associated with ustekinumab treatment
We then evaluated associations between SNPs and response to
ustekinumab therapy using drug survival as outcome, comparing
genotypes of responders with those of primary nonresponders.
Five of the analyzed SNPs showed nominal statistical signiﬁcance
(Po0.05) for both crude and adjusted ORs (Supplementary
Table 5), none of which remained signiﬁcant after controlling for
FDR. Next, associations of each SNP and response to ustekinumab
therapy were evaluated using PASI reduction as outcome,
comparing genotypes of good responders with those of
nonresponders under a dominant model. Six of the analyzed
SNPs showed nominal statistical signiﬁcance (Po0.05) for both
crude and adjusted ORs (Supplementary Table 6). Four associa-
tions remained signiﬁcant after controlling for FDR, the variant
alleles of TIRAP (rs8177374) (OR: 9.42, P= 0.0051, q= 0.19) and TLR5
(rs5744174) (OR: 5.26, P= 0.0012, q= 0.19) were associated with
beneﬁcial response and the variant alleles of IL1Β (rs1143623) (OR:
0.25, P= 0.0049) and IL1Β (rs1143627; r2 = 0.83) (OR: 0.24,
P= 0.0042, q= 0.19) were associated with nonresponse (Table 2).
Haplotype analysis for both treatments
Polymorphisms in the IL1Β gene were associated with response to
both treatments when we looked at the secondary outcome. To
assess whether any haplotypes could explain these associations,
we performed haplotype analysis with PASI reduction as the
response criterion (Supplementary Tables 7 and 8). Four haplo-
types described all of the observed genotypes in both groups,
excluding ﬁve patients who were treated with anti-TNF and four
patients who were treated with ustekinumab because of missing
genotype data. With haplotype combination 11 (rs4848306AA,
rs1143623GG and rs1143627TT) as reference, the haplotype
combinations 22 (rs4848306GG, rs1143623CC and rs1143627CC)
(OR: 0.22, 95% conﬁdence interval: 0.05–0.95, P= 0.043) and 12
(rs4848306AG, rs1143623GC and rs1143627TC) (OR: 0.28, 95%
conﬁdence interval: 0.09–0.84, P= 0.023) were associated with
nonresponse to anti-TNF (Supplementary Table 7). Haplotype
combination 12 (OR: 0.12, 95% conﬁdence interval: 0.03–0.54,
P= 0.006) was associated with nonresponse to ustekinumab
(Supplementary Table 8).
Table 1. Clinical and demographic characters for all the patients included, the anti-TNF cohort and the ustekinumab cohort
All patients Anti-TNF cohort Ustekinumab
cohort
Patients, no. 478 376 230
Female, no. (%) 193 (40) 145 (39) 107 (46)
Age, years
Age at baseline, mean (s.d.) 44 (14) 43 (14) 44 (14)
Disease duration, years
Duration at baseline, mean (s.d.) 20 (13) 20 (13) 21 (13)
A= 295 (62%) A= 248 (66%) A= 133 (58%)
BMI at baseline, mean (s.d.) 28 (6) 28 (6) 29 (6)
A= 177 (37%) A= 146 (39%) A= 102 (44%)
Psoriatic arthritis, no. (%) 148 (31) 126 (34) 50 (22)
Concomitant methotrexate, no. (%) 67 (16) 55 (16) 28 (13)
A= 432 (90%) A= 340 (90%) A= 220 (96%)
Biological treatment, no. (%)
Adalimumab 216 (45.19) 218 (57.98) —
Etanercept 106 (22.18) 103 (27.39) —
Inﬂiximab 55 (11.51) 55 (14.61) —
Ustekinumab 97 (20.29) — 230 (100)
Efalizumab 4 (0.84) — —
Biological naive — 358 (95) 95 (41)
PASI scores, mean (s.d.)
PASI at baseline 13.2 (7.8) 13.5 (7.8) 9.9 (7.2)
A= 365 (76%) A= 297 (79%) A= 185 (80%)
PASI at 3 months 3.0 (4.0) 3.2 (4.2) 2.9 (3.6)
A= 329 (69%) A= 269 (72%) A= 165 (72%)
PASI at 6 months 2.3 (3.5) 2.2 (3.1) 2.4 (3.4)
A= 291 (61%) A= 233 (62%) A= 146 (63%)
Abbreviations: A, available observations; BMI, body mass index; PASI, Psoriasis Area and Severity Index; TNF, tumor necrosis factor.
SNPs associated with biological treatment
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DISCUSSION
Here, 62 SNPs in 44 genes were successfully genotyped. With a
FDR of o0.20 we identiﬁed 6 SNPs that were associated with
responses to anti-TNF drug therapy, 4 that were associated
with responses to ustekinumab, and 2 of which were associated
with responses to both treatments. To our knowledge, none of the
SNPs identiﬁed to be associated with response to psoriasis
treatment have been reported previously.
The variant allele of LY96 (rs11465996), related to a high level of
MD-2 (ref. 17) (required for TLR2 and TLR4 to respond to
lipopolysaccharide), was associated with nonresponse to anti-
TNF therapy. Two SNPs in TLR2 (rs11938228 and rs4696480) with
unknown function were associated with nonresponse, and this
might indicate that TLR2 activity is associated with anti-TNF
treatment, although the unknown function of the two SNPs makes
the results difﬁcult to interpret in a biological context. Similar
associations for TLR2 (rs11938228, rs4696480) have been found
when treating inﬂammatory bowel disease with anti-TNF, and for
LY96 (rs11465996) when treating ulcerative colitis with anti-TNF,6
supporting the notion of a possible association. Furthermore, a
decrease in TLR2 levels has been found to be correlated with a
decrease in PASI when treating psoriasis with anti-TNF agents18
that could support the current ﬁndings.
In patients treated with anti-TNF, the variant alleles of IL1Β
(rs1143623 and rs1143627) were associated with nonresponse. In
single-polymorphism context the variant alleles of these two SNPs
are associated with reduced IL-1β transcription,19,20 but in the
haplotype context, which is the dominating haplotype in
Caucasians, the variant alleles of these two SNPs led to increased
transcription of IL-1β,21 indicating that a genetically determined
high level of IL-1β is associated with nonresponse to anti-TNF
treatment. In agreement with our current ﬁndings, an elevated
IL-1β level has been associated with an unfavorable response to
inﬂiximab in inﬂammatory bowel disease.22 In our study, patients
with haplotypes associated with increased transcription of IL-1β
were less likely to respond to anti-TNF treatment,21 further
supporting the ﬁndings. In patients treated with ustekinumab, the
same associations for IL1Β (rs1143623 and rs1143627) were seen,
and the same haplotype conveying increased IL-1β transcription
was associated with nonresponse. The variant allele of TLR5
(rs5744174), which is related to decreased IL-1β and IL-6 mRNA,23
and increased levels of CCL20 (ref. 24) and IFN-γ25 were associated
with beneﬁcial response to ustekinumab, again indicating that an
increased IL-1β level may be unfavorable when treating psoriasis
with ustekinumab. However, the variant allele of TLR2 (rs3804099),
which is related to high levels of TNF-α, IL-1β and IL-6 and a
reduced MYD88 level,26 was nominally associated with a beneﬁcial
response, and this might indicate that not only the level of IL-1β
but also the relative abundance of cytokines is crucial for response
to ustekinumab treatment.
For patients treated with ustekinumab, variants related to
an increased level of IFN-γ (TLR5 (rs5744174)25 and TIRAP
(rs8177374)27) appears to be associated with a beneﬁcial response.
Moreover, the variant allele of IFNG (rs2430561)—conveying high
levels of IFN-γ28,29 —was found to be nominally associated with a
beneﬁcial response to ustekinumab. Furthermore, when we
adjusted for gender, age, psoriatic arthritis and previous treat-
ments, the variant allele of TBX21 (rs17250932), which is related to
decreased IFN-γ level,30 was nominally associated with nonre-
sponse. IFN-γ is highly upregulated in psoriasis and is one of the
Table 2. Crude and adjusted OR for carriers of the variant allele compared with homozygous carriers of the wild-type allele for SNPs signiﬁcant
controlling the FDR at 20% when treating psoriasis with anti-TNF or ustekinumab
Gene (W/Vt) Rs number OR (95% CI), q-value/crude OR (95% CI), q-value/adjusteda Effect of variant allele
Response to anti-TNF treatment based on drug survival (R vs PN)
TLR9
G/A rs352139 2.42 (1.32–4.44), 0.19 2.17 (1.15–4.09), 0.33 Increased expression of TLR952 b
Response to anti-TNF treatment based on PASI reduction after 3 months (G vs N)
IL1B
G/C rs1143623 0.42 (0.21–0.83), 0.30 0.35 (0.17–0.71), 0.19 Decreased IL-1β19 c but is only found in haplotypes with
increased IL-1β transcription21 b
T/C rs1143627 0.36 (0.17–0.74), 0.19 0.28 (0.13–0.62), 0.19 Decreased expression19,20 c,d but is only seen in
haplotypes with increased IL-1β transcription21 b
LY96
C/G rs11465996 0.38 (0.19–0.77), 0.23 0.33 (0.15–0.71), 0.19 Increased MD-2 and TNF-α level17 e, c
TLR2
C/A rs11938228 0.36 (0.18–0.74), 0.19 0.30 (0.14–0.64), 0.19 Unknown
A/T rs4696480 0.31 (0.12–0.78), 0.19 0.22 (0.08–0.59), 0.19 Unknown
Response to ustekinumab treatment based on PASI reduction after 3 months (G vs N)
IL1B
G/C rs1143623 0.21 (0.09–0.52), 0.19 0.25 (0.09–0.66), 0.19 Decreased IL-1β19 c but is only found in haplotypes with
increased IL-1β transcription21 b
T/C rs1143627 0.24 (0.09–0.63), 0.19 0.25 (0.09–0.73), 0.30 Decreased expression19,20 c, f but is only seen in
haplotypes with increased IL-1β transcription21 b
TIRAP
C/T rs8177374 8.62 (1.92–38.64), 0.19 9.42 (1.96–45.30), 0.19 Increased TNF-α, IFN-γ and IL-627 c
TLR5
T/C rs5744174 4.43 (1.86–10.56), 0.19 5.26 (1.93–14.38), 0.19 Decreased mRNA levels of IL-6 and IL-1β23 d, increased
production of CCL2024 c and IFN-γ level25 c
Abbreviations: CI, conﬁdence interval; FDR, false discovery rate; G vs N, good responders (⩾ PASI75) vs nonresponders (oPASI50); IFN-γ, interferon-γ;
IL, interleukin; OR, odds ratio (41.00 associated with beneﬁcial response); PASI, Psoriasis Area and Severity Index; R vs PN, responders (⩾225 days of treatment)
vs primary nonresponders (o225 days of treatment and no effect of treatment); SNP, single-nucleotide polymorphism; TLR, Toll-like receptor; TNF, tumor
necrosis factor; Vt, variant allele; W, wild-type allele. aAdjusted for age, gender, psoriatic arthritis and previous treatments. bFunction examined by luciferase
reporter assay. cFunction examined by enzyme-linked immunosorbent assay. dFunction examined by electrophoretic mobility shift assay. eFunction examined
by ﬂow cytometry. fFunction examined by real-time PCR.
SNPs associated with biological treatment
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key cytokines.2 A decrease in IFN-γ levels has been shown to be
correlated with a decrease in PASI scores.31 By blocking IL-12p40,
ustekinumab blocks the IL-12-dependent Th1 production of IFN-γ
that could explain why a genetically determined elevated level of
IFN-γ is associated with a beneﬁcial response. However, we cannot
exclude the possibility that the associations observed are because
of factors other than the increased IFN-γ. Moreover, our results are
supported by a Dutch pilot study32 in which patients who
responded to ustekinumab had a strong IFN signature compared
with that of nonresponders.
In order to increase the statistical power, we analyzed all
anti-TNF treatments as one, a commonly used strategy.33–43 For
all signiﬁcant associations, except TLR9 (rs352139) and LY96
(rs11465996), similar tendencies were observed for ORs for each
of the anti-TNF agents (data available on request). To our
knowledge, this is one of the largest cohorts for evaluation of
response in patients treated with ustekinumab44,45 and the
second largest for evaluation of anti-TNF; only a Canadian study
(also involving treatment primarily for psoriatic arthritis) had more
patients.46 In the present study, some of the patients were
included in both the ustekinumab cohort and the anti-TNF cohort;
however, as the treatments target different pathways, including
previously treated patients is a commonly used approach.47–50
Efﬁcacy of treatments was evaluated based on both drug survival
of 6 months and relative PASI reduction after 3 months. We
cannot exclude that categorization of response for some of the
patients may be inﬂuenced by other factors, for example,
comedication, patients’ preferences or dose changes, although
this is highly unlikely as these factors primarily affect the overall
long-term drug survival and not the short-term response. Even
though drug survival was our primary outcome, the majority of
the associations were observed evaluating treatment based on
PASI that could indicate outcomes based on PASI scores to be
more suitable in future studies.
With increasing number of test performed, the risk of
false positive associations similarly increases. To take this into
account, we corrected for multiple testing by controlling the
false discovery rate at 0.20. By doing so we found that eight of the
SNPs evaluated were associated with response to one or both
treatments and the majority were functionally and biologically
plausible according to current knowledge and previous ﬁndings.
Given the number of signiﬁcant associations and the selected FDR
of 0.20, approximately two of the reported associations would be
expected to be false positives. However, by choosing functional
polymorphisms possibly involved in the pathogenesis and
treatment of psoriasis, we increased the a priori likelihood of true
associations. The SNPs were evaluated for genotyping errors by
assessing Hardy–Weinberg equilibrium. This was performed in
a control group of healthy Danish blood donors51 as Hardy–
Weinberg equilibrium cannot be assessed in the current highly
selected study group of patients with psoriasis selected for
treatment with biological therapy. The control group was
genotyped by the same method at the same laboratory. All SNPs
were in Hardy–Weinberg equilibrium. The overall characteristics of
the current group resample that of the entire DERMBIO database,
apart from a slightly higher proportion of female patients in the
current study.
In conclusion, we have shown that genetic variants in genes
that regulate cytokines involved in psoriasis are associated with
response when psoriasis is treated with either anti-TNF or
ustekinumab. Genetic variants related to elevated levels of IL-1β
appear to be unfavorable when treating psoriasis with either anti-
TNF or ustekinumab, whereas patients with genetic variants
related to a high level of IFN-γ appear to be more likely to respond
when being treating with ustekinumab. As none of our results
have been associated with response to biological treatment of
psoriasis previously, they should be validated in independent
cohorts.
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